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A molecular switch controls interspecies prion disease
transmission in mice
Abstract
Transmissible spongiform encephalopathies are lethal neurodegenerative disorders that present with
aggregated forms of the cellular prion protein (PrPC), which are known as PrPSc. Prions from different
species vary considerably in their transmissibility to xenogeneic hosts. The variable transmission
barriers depend on sequence differences between incoming PrPSc and host PrPC and additionally, on
strain-dependent conformational properties of PrPSc. The beta2-alpha2 loop region within PrPC varies
substantially between species, with its structure being influenced by the residue types in the 2 amino
acid sequence positions 170 (most commonly S or N) and 174 (N or T). In this study, we inoculated
prions from 5 different species into transgenic mice expressing either disordered-loop or rigid-loop
PrPC variants. Similar beta2-alpha2 loop structures correlated with efficient transmission, whereas
dissimilar loops correlated with strong transmission barriers. We then classified literature data on
cross-species transmission according to the 170S/N polymorphism. Transmission barriers were
generally low between species with the same amino acid residue in position 170 and high between those
with different residues. These findings point to a triggering role of the local beta2-alpha2 loop structure
for prion transmissibility between different species.
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Transmissible	spongiform	encephalopathies	are	lethal	neurodegenerative	disorders	that	present	with	aggre-
gated	forms	of	the	cellular	prion	protein	(PrPC),	which	are	known	as	PrPSc.	Prions	from	different	species	
vary	considerably	in	their	transmissibility	to	xenogeneic	hosts.	The	variable	transmission	barriers	depend	on	
sequence	differences	between	incoming	PrPSc	and	host	PrPC	and	additionally,	on	strain-dependent	confor-
mational	properties	of	PrPSc.	The	β2-α2	loop	region	within	PrPC	varies	substantially	between	species,	with	its	
structure	being	influenced	by	the	residue	types	in	the	2	amino	acid	sequence	positions	170	(most	commonly	
S	or	N)	and	174	(N	or	T).	In	this	study,	we	inoculated	prions	from	5	different	species	into	transgenic	mice	
expressing	either	disordered-loop	or	rigid-loop	PrPC	variants.	Similar	β2-α2	loop	structures	correlated	with	
efficient	transmission,	whereas	dissimilar	loops	correlated	with	strong	transmission	barriers.	We	then	classi-
fied	literature	data	on	cross-species	transmission	according	to	the	170S/N	polymorphism.	Transmission	bar-
riers	were	generally	low	between	species	with	the	same	amino	acid	residue	in	position	170	and	high	between	
those	with	different	residues.	These	findings	point	to	a	triggering	role	of	the	local	β2-α2	loop	structure	for	
prion	transmissibility	between	different	species.
Introduction
Transmissible spongiform encephalopathies (TSEs) are lethal neu-
rodegenerative disorders that include kuru and Creutzfeldt-Jakob 
disease (CJD) in humans, bovine spongiform encephalopathy 
(BSE) in cows, scrapie in sheep and goats, and chronic wasting dis-
ease (CWD) in cervids (1). A crucial component of the infectious 
agent is PrPSc, a highly aggregated, β-sheet–rich isoform of the cel-
lular prion protein (PrPC) (2, 3).
Prion diseases can occur as distinct strains within species 
expressing identical PrP amino acid sequences (4). Prion strains 
have originally been defined by transmission to mice, in which they 
show different incubation periods (ips) and variable brain regions 
targeted (5–7). Evidence is accumulating that distinct strains rep-
resent different PrPSc conformations (8–11).
There is evidence that interspecies prion transmission occurs in 
nature, and it has thus become an important food safety issue. 
Dietary exposure to beef contaminated with the BSE agent is 
believed to have caused nearly 200 cases of variant CJD (vCJD) in 
humans (12–15) as well as spongiform encephalopathies in domes-
tic cats and British zoo animals (16–19). Prion transmission across 
species barriers has been replicated experimentally and typically 
leads to incomplete attack rates and to prolonged, highly variable 
ips (20). Understanding the factors that dictate species barriers is 
crucial for assessing the risk for human prion disease, particularly 
as new prion strains may arise in food animals (21–24).
Experimental studies of species and strain barriers in vitro and 
in vivo indicate that certain amino acid positions have an out-
standingly strong influence on prion transmission among species 
with heterologous prion protein (Prnp) sequences (4, 25–32). For 
example, hamsters resist infection with mouse prions, although 
the hamster and mouse Prnp sequences differ at only 9 residues 
(30–32). Similarly, knock-in mice that only differ from WT mice at 
codon 101 of the Prnp allele show highly divergent susceptibility to 
sheep scrapie, BSE, and CJD (33, 34).
Susceptibility to natural prion infections may also be influ-
enced by Prnp polymorphisms. Humans are polymorphic at 
PRNP codon 129 (methionine/valine). While approximately 38% 
of Europeans are 129MM homozygous, 100% of the confirmed 
vCJD cases have occurred in 129MM patients (35), indicating 
selective susceptibility of this allotype to BSE prions. Since the 
efficiency of TSE transmission into a new species further appears 
to vary depending on the prion strain (33, 36, 37), the increased 
susceptibility of humans carrying the 129MM alleles may not be 
maintained with future BSE strains.
Although the amino acid sequence of PrPC is overall highly con-
served among mammals, the β2-α2 loop encompassing residues 
165–175 is a site of outstandingly high sequence diversity (38). 
The 3-dimensional structure of PrPC immediately led to the iden-
tification of this loop as a key part of the surface epitope that 
might influence species barriers (39, 40), and this hypothesis 
also received support from molecular dynamics simulations (41). 
Mature PrPC contains a flexibly unstructured N-terminal 100-
residue “tail” and a globular C-terminal domain of similar size, 
which contains 3 α-helices and a short antiparallel β-sheet (40, 
42, 43). The β2-α2 loop is structurally polymorphic in that amino 
acid sequences that contain 170S and 174N form a poorly defined 
loop in the NMR solution structures at 20°C (44–47), whereas 
sequences that contain 170N, or 170N and 174T (numbering 
according to ref. 48) have a well-defined loop (49–51). Here, we 
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used transgenic mice expressing prion proteins that differ in dis-
crete sequence positions of the β2-α2 loop to further investigate 
the effect of the loop structure on interspecies prion transmis-
sion. We found that sequence variations affecting only the β2-α2 
loop conformation can significantly impact cross-species suscep-
tibility to a broad array of prion diseases.
Results
To determine the impact of the loop sequence on interspecies trans-
mission, we used 2 lines of transgenic mice expressing PrPC variants 
that differ by 2 amino acid residues. tga20 mice overexpressed WT 
mouse PrP, whereas tg1020 mice overexpressed a “rigid loop” (RL) 
variant of PrP with S170N and N174T substitutions (Figure 1A). 
In both mouse lines, the transgene was expressed in the context 
of a “half-genomic” prion minigene construct. Expression levels 
were approximately 6- and 3-fold higher in tga20 and tg1020 mice, 
respectively, than those for endogenous PrPC (52, 53).
Mice were inoculated with prions derived from 5 species (Figure 1A), 
for which PrPC 3-dimensional structures have been fully character-
ized by solution NMR spectroscopy: sheep, cattle, cervid, hamster, 
and mouse (Figure 1B). The overall structure of the C-terminal glob-
ular domain is nearly identical among these 5 species (Figure 1B), 
yet they differ in the local conformations of the β2-α2 loop (Figure 1C) 
encompassing residues 165–175 (40, 44–47, 50, 51).
Inoculation with mouse scrapie strains. All prion strains used for the 
inoculations were proteinase K (PK) resistant. Therefore, the crite-
rion used for determining transmission to tg1020 and tga20 mice 
was the presence of PK-resistant PrPSc in the brain of the recipients 
as well as development of a rapidly progressive neurologic disease 
with widespread spongiosis. To assess the susceptibility of WT-PrP 
and RL-PrP mice to mouse-adapted scrapie, we inoculated tga20 
and tg1020 mice intracerebrally with 104 LD50 of Rocky Mountain 
Laboratory (scrapie strain passage 5, referred to herein as RML5) 
prions (Figure 2A). tga20 mice developed terminal prion disease in 
74 ± 6 days, whereas tg1020 mice developed disease after a much 
longer and more variable ip (323 ± 92 days; unpaired, 2-tailed Stu-
dent’s t test, P = 0.002; Figure 2B and Table 1). The prion-contain-
ing brain homogenate recovered from the latter mice was termed 
RL-RML1 (RL-passaged RML, first passage). WT mice developed 
scrapie in 170 ± 12 days after inoculation with 103 log LD50 of the 
same inoculum (Figure 2B), indicating that RL-PrP mice developed 
disease with a 47% increase in the ip compared with the WT mice.
Figure 1
Amino acid sequence and 3-dimensional structure comparisons for WT mouse PrPC (Prnp a), mouse RL-PrPC, and for WT-PrPC of 4 additional 
mammalian species. (A) PrP amino acid sequence of PrP from mouse (mPrP; Mus musculus, AAA39997) and the RL variant thereof and Syrian 
hamster (shPrP; Mesocricetus auratus, AAA37091), elk (ePrP; Cervus elaphus nelsoni, AAB94788), sheep (ovPrP; Ovis aries, ABC61639), and 
cattle PrP (bPrP; Bos taurus, ABU97893). For mouse PrPC, the residues 23−231 are shown. For the RL variant and the other species, the only 
amino acids indicated are those that differ from the mouse PrP sequence, with identical amino acids indicated by dots and deletions indicated by 
dashes. The shaded region indicates the β2-α2 loop region, and the “X” in the ovine indicates a polymorphic residue position (Q/R). At the top, the 
regular secondary structure elements are shown. (B) Backbone superpositions of residues 125−228 of RL-PrPC (gray) with mouse PrPC (dark 
blue), Syrian hamster PrPC (light blue), elk PrPC (yellow), sheep PrPC (pink), and cattle PrPC (purple) (adapted from refs. 44–47, 51). A larger 
view of the region in the red box is shown in C. (C) Backbone fold of residues 165−172 in RL-PrPC, mouse PrPC, Syrian hamster PrPC, elk PrPC, 
sheep PrPC, and cattle PrPC. The radius of the cylindrical rods representing the polypeptide chains is proportional to the mean global backbone 
displacement for residues from 20 conformers used to represent the NMR structures. The same color code is used as in B.
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RML-PrPSc aggregates in brain displayed similar morpholo-
gies in tga20 and tg1020 mice, consisting of widespread deposits 
visible by immunohistochemistry (Figure 2C). Elderly uninocu-
lated tg1020 mice developed a spontaneous transmissible prion 
disease, with focal cerebral PrP plaques (53), yet the morphol-
ogy of these spontaneous deposits was profoundly different 
from the widespread diffuse deposits developing in inoculated 
mice. Also, N-terminally cleaved PrP never acquired PK resis-
tance of all 3 glycoforms in spontaneously sick tg1020 mice. 
Therefore, the PK-resistant PrPSc detected in tg1020 and tga20 
mice indicates that transmission of RML prions had occurred 
in both strains of host mice.
Inoculation of RL-RML1 homogenate into a further generation 
of tg1020 mice resulted in a shortening of the ip and a reduction 
of variability by nearly 50%, to 171 ± 11 days (Figure 2, A and B, 
and Table 1). Hence, the substitutions of residues 170 and 174 
had created a species barrier for RML prions, which was overcome 
by serial passaging. Conversely, back passage of the RL-RML1 
inoculum into tga20 mice led to a more than 50% increase in the 
ip and to a 5-fold increase in variability (186 ± 33 days; Figure 2B 
and Table 1). The latter results point to a species barrier erected 
by the WT-Prnp sequence against RL-PrP prions. In conclusion, 
mouse prions could be adapted to hosts expressing either WT or 
RL Prnp; both resulting inocula were readily propagated in hosts 
Figure 2
The RL induces a species barrier for RML infection. (A) Schematic illustrating the passages of RML mouse-adapted scrapie into the tga20 and 
tg1020 mice. The labels i–iv indicate the inoculation groups labeled in the survival curves in B. (B) RML induces prion disease in tg1020 mice 
after a prolonged, highly variable ip (blue line). In contrast, tga20 mice infected with RML have a short, invariable ip (red line). WT mice infected 
with RML are shown for comparison. RL-RML1 leads to a shortened, more consistent ip in tg1020 mice but a prolonged, variable ip in tga20 
mice, indicative of a species barrier effect. (C) Diffuse PrPSc staining occurs in the brain after RML infection of tg1020 and tga20 mice. Only 
aggregates in tg1020 mice were positive with PTAA staining (arrows). Scale bars: 400 μm (RML); 50 μm (PTAA). (D) Passage of the RL-RML 
resulted in abundant PrPSc deposits in tg1020 mice but very little PrPSc stain in tga20 mice, as shown by PrP immunohistochemistry (anti-PrP 
monoclonal antibody, SAF84). Histoblots of RL-RML also depict widespread distribution of PK-resistant PrP (PK concentration, 100 μg/ml). Scale 
bars: 200 μm (RL-RML); 500 μm (histoblot). (E) The correlation diagram of emission intensity of PTAA-bound PrP aggregates at wavelength 
ratios 531 nm/642 nm (R531/642) and 531 nm/the emission maxima (R531/Emax) shows the high variability of the RL-RML1 in tg1020 mice. M-NS, 
mouse-adapted sheep scrapie. RL-RML1 is a prion strain derived from RL mice infected with RML. (F) Westerns blots of the RL-RML1 passage 
show homogeneous levels of PrPSc in tg1020 mice but heterogenous levels in tga20 mice.
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expressing the same Prnp variant but were much less amenable to 
propagation in hosts expressing the other variant. This fulfills the 
definition of a species barrier.
RL-RML1 PrPSc aggregates were sparsely distributed in 
tga20 mice but were widespread in tg1020 mice, as shown by 
immunohistochemistry and histoblotting (Figure 2D). Neither 
RML nor RL-RML1 tissue deposits were stained by Congo red 
(Supplemental Figure 1; supplemental material available online 
with this article; doi:10.1172/JCI42051DS1). We stained brain sec-
tions with the fluorescent amyloidotropic dye, polythiophene ace-
tic acid (PTAA) (54). PTAA stains PrPSc deposits and emits distinct 
fluorescence spectra that report on the supramolecular arrange-
ment of protein aggregates.
All RML-infected tg1020 brains, but none of the tga20 brains, 
contained PTAA+ plaques (Figure 2C). We compared PTAA emis-
sions by plotting the fluorescence intensity ratio at 531 and 642 
nm (R531/642) against the ratio between the intensity at 531 nm 
and at the emission maximum (R531/Emax). The resulting values are 
independent of absolute fluorescence intensity and can discrimi-
nate among multiple prion strains (55, 56). PTAA emission charac-
teristics were highly variable among animals and sometimes even 
within individual animals, suggesting highly polymorphic PrPSc 
conformations in the first passage of RML (Figure 2E). However, 
none of the tga20 and tg1020 mice inoculated with RL-RML1 prions 
had PTAA+ plaques. This finding suggests that the supramolecular 
arrangements of PrPSc had changed drastically upon passage.
We then compared brain homogenates of tga20 and tg1020 mice 
inoculated with RL-RML1 by PK digestion followed by Western 
blotting. The concentration of PrPSc was relatively homogenous in 
tg1020 mice but highly variable in tga20 mice (Figure 2F). We con-
cluded that the S170N and N174T substitutions created a species 
barrier to RML prions, which was eventually overcome in the RL 
mice through multiple passages.
Inoculation with CWD infectious brain homogenate. We then inocu-
lated tg1020 and tga20 mice with CWD prions from a terminal, 
naturally infected mule deer. WT mice are resistant to infection 
with CWD prions (57, 58), whereas overexpression of WT Prnp 
renders tga20 mice susceptible to CWD — albeit after long ips (59). 
The mature PrPC sequences of mice and mule deer differ at 23 resi-
dues, but the 165–175 loop sequence in tg1020 mice is identical to 
that of deer and elk (Figure 1A).
CWD infection led to accelerated disease in 
tg1020 mice compared with tga20 mice (279 ± 48 
days and 543 ± 72 days, respectively; Figure 3A 
and Table 1) (unpaired, 2-tailed Student’s t test, 
P = 0.001). We detected abundant fine and 
clumped aggregates in hippocampus and cere-
bral cortex by using immunohistochemistry for 
PrP in tg1020 mice. The PTAA emission spectra 
were similar for all histologically visible aggre-
gates in the first CWD passage, with little vari-
ability within and between tg1020 animals.
Surprisingly, the second passage of RL-CWD 
in tg1020 mice resulted in a slight lengthen-
ing of the ip (Figure 3A and Table 1). Using 
immunohistochemistry for PrP and PTAA emis-
sion spectra, 2 conspicuously differing PrPSc 
aggregate morphologies emerged: (a) a noncon-
gophilic type, with a low R531/642 similar to the 
first passage, and (b) a rare, 50- to 100-μm dense 
congophilic type, with a high R531/642 (Figure 3B). The R531/642, 
which depends on fluorescence resonance transfer between PTAA 
molecules, indicated that the LCP chains were tightly packed in 
the noncongophilic aggregates and loosely packed in the congo-
philic aggregates (Figure 3C). Maybe the conformational variants 
were interfering with the conversion of each other, thereby result-
ing in an unexpectedly long ip.
We then investigated the biochemical profile of CWD-induced 
PrPSc in tg1020 brain homogenates using PK digestion and PrP 
immunoblotting. The first passage of CWD in tg1020 mice 
yielded barely detectable PK-resistant PrPSc. By the second pas-
sage, PK-resistant PrP showed the typical shift in electrophoretic 
mobility, suggesting that a PK-resistant form had become more 
abundant (Figure 3D).
We then assessed the effect of the PrPSc primary amino acid 
sequence on the strain properties by comparing a mouse-adapt-
ed CWD (M-CWD) strain with mule deer CWD in tg1020 mice. 
There was no significant difference in the ips: M-CWD–infected 
tg1020 mice (Figure 3E) and mule deer CWD–infected tg1020 
mice (Figure 3A) had ips of 252 ± 51 days and 279 ± 48 days, 
respectively (Student’s t test, P = 0.45).
PrP aggregates in the M-CWD–inoculated tg1020 brains his-
tologically appeared large and congophilic (Figure 3F), similar 
to the rare congophilic plaques seen in the RL-CWD–infected 
tg1020 mice and the M-CWD–infected tga20 mice (Figure 3, B 
and F). The LCP emission spectra R531/642 and R531/Emax were also 
similar (Figure 3G), with values that are indicative of loosely 
packed PTAA chains.
The above data indicate that after primary deer CWD inocula-
tion, RL-PrP may give rise to morphologically small, noncongo-
philic aggregates, leading to tight packing of PTAA, or large, con-
gophilic plaques, leading to looser packing of PTAA. In contrast, 
the M-CWD strain gave rise to a single morphology in both tga20 
and tg1020 mice, which appeared similar to the large congophilic 
plaques described above.
Inoculation of hamster scrapie into RL-PrP and WT-PrP mice. Mice 
were initially believed to be completely resistant to infection 
with particular strains of hamster prions (60), but an extensive 
series of experiments revealed that mice can replicate hamster pri-
ons subclinically (32). The hamster PrPC β2-α2 loop sequence is 
homologous with the RL-PrP sequence at position 170N and with 
Table 1
Passage of mouse, deer, hamster, cattle, and sheep TSEs into mice expressing 
mouse PrPC or RL-PrPC
TSE	 tga20	 tg1020
	 Attack	rate		 ip		 Attack	rate		 ip		
	 (no.	infected/total)	 (days)A	 (no.	infected/total)	 (days)A
RMLB 4/4 74 ± 6 4/4 323 ± 92
RL-RML1B 6/6 186 ± 33 6/6 171 ± 11
CWD 4/4 543 ± 72 4/4 279 ± 48
RL-CWD ND – 4/4 401 ± 28
M-CWD 4/4 162 ± 6 4/4 252 ± 51
Hamster scrapie 1/4 449 6/6 468 ± 24
BSE 4/4 281 ± 139 0/4 –C
Sheep scrapie 4/4 405 ± 26 0/4 –C
AMean ± SD. BRML infections were previously described (53). CMice did not develop evi-
dence of TSE. ND, not done.
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the WT mouse sequence at 174N. To determine whether either 
WT-PrP or RL-PrP, or both, could support hamster prion replica-
tion, we inoculated tga20 and tg1020 mice with the Sc237 strain 
of hamster prions. The ips were consistently more than 400 days 
for all mice, but the attack rate varied markedly. Whereas 6 out 
of 6 tg1020 mice showed N-terminally cleaved, PK-resistant PrPSc 
accumulation in histoblot and Western blot assays (Figure 4, A 
and B), versus a background of 0 out of 13 uninoculated tg1020 
mice (Supplemental Figure 2), only 1 out of 4 tga20 mice had any 
detectable PrPSc, even following concentration of PrPSc by sodium 
phosphotungstic acid precipitation (Figure 4B). tg1020 mice, but 
not tga20 mice, showed conspicuous spongiform encephalopathy, 
which was particularly evident in the cerebral cortex (Figure 4C). 
PrPSc aggregates were finely granular and diffusely distributed 
(Figure 4A). The Congo red, PTAA, and polythiophene methyl 
imidazole (PTMI) stains were negative (Supplemental Figures 1 
and 3), precluding emission spectra comparisons with RL-RML 
or RL-CWD. We concluded that hamster scrapie could be con-
Figure 3
Mule deer CWD infection of tga20 and tg1020 mice. (A) A survival curve of tga20 and tg1020 mice infected with mule deer CWD shows a 
shorter and less variable ip in tg1020 mice (blue line), which was slightly longer on second passage (referred to as RL-CWD). (B) Similar to deer, 
CWD-PrPSc aggregates in tg1020 mice on first passage are small, irregular, and noncongophilic (middle panel). Upon second passage, large 
unicentric, congophilic plaques emerge (RL-CWD, right panel). Cr, Congo red. (C) The first passage of CWD in tg1020 mice (RL-CWD, 1st; 
black circles) shows a highly consistent emission profile of PTAA-bound PrP aggregates, whereas on second passage (RL-CWD, 2nd; purple 
diamonds), both the emission ratio from the first passage and a new ratio from the congophilic plaques emerge. Murine-adapted sheep scrapie 
(green square) and M-CWD (red triangle) in tga20 mice are also shown for comparison. (D) CWD in tg1020 was primarily PK sensitive on the 
first passage in tg1020 mice. By the second passage, RL-CWD was PK-resistant (lanes 1–3). M-CWD in tg1020 mice showed weakly PK-resis-
tant PrP (lanes 4–6). (E) tg1020 mice inoculated with M-CWD have a slightly longer and more variable ip, as compared with the tga20 mice. (F) 
PrP aggregates of M-CWD in tg1020 and tga20 mice are similarly dense and congophilic. (G) The PTAA emission ratio of M-CWD inoculated 
into the tg1020 mice (RL-MCWD, purple diamond) is more closely similar to that of M-CWD in tga20 mice than to that of murine-adapted sheep 
scrapie in tga20 mice. Scale bars: 50 μm.
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sistently transmitted to tg1020 but not tga20 mice. The long ip 
suggests either inefficient transmission or generation of PrPSc 
aggregates with low toxicity.
Inoculation with BSE and sheep scrapie. We inoculated tg1020 and tga20 
mice with BSE and sheep scrapie isolates (Swiss BSE and Colorado 
sheep scrapie from single animals). Cattle, sheep, and mouse PrP 
protein sequences are identical at the β2-α2 loop, and both BSE and 
sheep scrapie isolates can infect tga20 mice, as previously reported 
(56). After inoculation with BSE or sheep scrapie, aged tg1020 mice 
(>300 days old) developed weight loss and mild paraparesis as well 
as rare RL-PrP plaques in the hippocampus. However, in the tg1020 
mice there was no evidence for BSE or sheep scrapie transmission 
by any method. PrP histoblots and Western blots were consistently 
negative for PK-resistant PrPSc (Supplemental Figures 2 and 4).
In vitro cross-species PrPSc amplification using protein misfolding cyclic 
amplification. To assess whether the transmission barrier induced by 
the S170N and N174T substitutions could be reproduced in vitro, 
we performed protein misfolding cyclic amplification (PMCA) exper-
iments, using the tg1020 and tga20 brain as a substrate. We seeded the 
PMCA reaction with RML mouse prions, 263K hamster scrapie, deer 
CWD, and Colorado sheep scrapie. Six separate samples of tg1020 
and tga20 brain were seeded with each prion strain and amplified for 
5 rounds (Table 2 and Supplemental Figure 5). We found that by the 
fifth round, tg1020 brain homogenates yielded PK-resistant PrP in 
100% of samples seeded with hamster scrapie and 83% of samples 
seeded with CWD, compared with only 17% and 50% of tga20 brain 
homogenates seeded with hamster scrapie and CWD, respectively. 
tg1020 and tga20 brain homogenate led to PK-resistant PrP in all 
samples seeded with RML but in no samples seeded with sheep scra-
pie. Therefore, the PMCA experiments largely reproduced our in vivo 
findings; the main difference occurred with sheep scrapie, in which 
PK-resistant PrPSc was not detected in any of the tga20 and tg1020 
samples. Although we have shown that the tga20 mice and tg1020 
mice were both susceptible to RML infection, the difference in the ip 
was not revealed by differences in seeding ability using PMCA.
Discussion
170 and 174 are positions that can modulate prion transmission. The 
S170N and N174T substitutions in the β2-α2 loop of PrPC erect-
ed a complete barrier to TSEs derived from 2 different host spe-
cies, cattle and sheep (Table 3). Conversely, the very strong bar-
rier of mice against hamster prions was completely ablated, as 
hamster prions infected all mice expressing RL-PrPC (Table 3). 
The potent impact on species barriers caused by 2 amino acid 
substitutions indicates that prion species barriers may be pro-
foundly altered in humans or animals expressing polymor-
phisms or mutant PrP molecules. Thus, human or animal TSEs 
may be replicated by mutant molecules, even when otherwise 
strong species barriers are known to exist.
TSE infection in the tg1020 mice. We have previously reported that 
tg1020 mice spontaneously develop a new strain of TSE (53). The 
resulting disease may confound the assessment of TSE transmis-
sion to prion-inoculated tg1020 mice. On the other hand, several 
traits allowed for unequivocal differentiation between transmit-
ted and spontaneous prion disease. First, immunoblots showed 
the canonical “shift” in electrophoretic mobility in PrPSc recov-
ered from TSE-infected tg1020 mice after PK digestion. This shift 
has never been detected in spontaneously sick tg1020 mice. Sec-
ond, inoculated mice showed widespread deposition of PrPSc in 
the brain, which extended to regions, such as the thalamus, in 
which aggregates have never been observed in spontaneous dis-
ease. Third, the staining profiles of specific LCP dyes and their 
fluorescence emission spectra differed vastly between inoculated 
and spontaneously sick tg1020 mice. For example, PTAA failed 
to stain any brain sections of RL-RML2 and RL hamster strains 
in tg1020 mice, whereas it consistently labeled spontaneously 
appearing prion aggregates. Taken together, these features sup-
port that the instances of disease reported in this study represent 
bona fide transmission of TSE rather than spontaneous disease 
typical of noninoculated tg1020 mice.
tga20 mice express 2-fold more PrPC than the tg1020 mice and 
would therefore have been expected to develop prion disease after 
a shorter ip if there was no transmission barrier induced by the 
S170N and N174T substitutions. However, the tga20 mice only 
developed prion disease with a shorter ip after inoculation with 
RML prions and actually had a longer ip after inoculation with 
CWD prions. With RML infection, the tg1020 mice showed clear 
evidence of a transmission barrier, in that the ip exceeded that of 
lower expressing WT mice and shortened by 50% upon second 
passage. Together, the data clearly support that the differences 
Figure 4
Hamster scrapie infects tg1020 mice. 
(A) PK-resistant PrP is clearly evident 
in the frozen brain sections of tg1020 
mice (arrow) but not tga20 mice. Scale 
bar: 1 mm. (B) PrPSc is predominantly 
diglycosylated and present in 6 out 
of 6 tg1020 (top panel) mice infected 
with hamster scrapie, but it is seen 
in only 1 out of 4 tga20 mice (bottom 
panel). UI, uninfected. (C) The cere-
bral cortex of tg1020 and tga20 mice 
infected with hamster scrapie shows 
extensive spongiform degeneration in 
the tg1020 mice (denoted by arrow-
heads). Scale bar: 100 μm.
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in prion susceptibility are due to the S170N and N174T substitu-
tions and not due to the differences in PrPC expression.
Consistency of in vivo and in vitro studies of species barriers. Two 
decades of published studies indicate that the penetrance of cross-
species transmission is affected by the sequence similarity between 
the host PrPC and the incoming PrPSc (61). Even single–amino acid 
polymorphisms can radically alter the transmissibility profiles of 
individual prion strains (62–69). Scrapie infection of cells express-
ing variant sequences of PrPC has also revealed the striking effects 
of mutations on the efficiency of conversion of PrPC to PrPSc (70).
Hamster prions were successfully transmitted only to tg1020 
mice and not to tga20 mice. The hamster PrP sequence is homolo-
gous to RL-PrP at position 170 and to WT-PrP at position 174, sug-
gesting that homology at 170 was critical for transmission. Stud-
ies of prion transmission in bank voles and PMCA experiments 
with CWD in a panel of mammalian species also implicate resi-
due 170 as a key position for influencing species barriers (37, 71). 
These results can be rationalized by classifying TSE hosts into 
2 groups: 170S animals that include cattle, sheep, and mice and 
170N animals that include elk, deer, hamsters, and RL mice.
Here, we show that susceptibility to a number of prion strains 
seemed to be driven by homology at position 170, although fur-
ther experiments with single mutants would be necessary to fully 
clarify the relative contributions of residues at positions 170 and 
174. tga20 mice could readily convert other 170S prions, such as 
cattle BSE and classical sheep scrapie, but not the 170N prions, 
such as hamster scrapie. While the overexpressing tga20 mice could 
convert 170N mule deer CWD prions after a long ip (59), WT mice 
are resistant to CWD (57, 58). Conversely, tg1020 mice could con-
vert 170N hamster scrapie and mule deer CWD but completely 
resisted infection with 170S sheep scrapie and BSE (Table 3). 
While tg1020 mice may have developed spontaneous infectivity, 
which would have been detected on further passages, this possibil-
ity would not have interfered with the above interpretation.
The above results prompted us to reinterpret published prion 
transmission experiments and epidemiologic studies in the con-
text of the 170S/170N transmission barrier. In accordance with our 
predictions, prions are readily transmitted within 170S mammals: 
sheep scrapie prions infect cattle (72–74) and mice (75, 76), and 
cattle BSE prions readily infect sheep (77–79) and mice (14, 80). 
BSE (170S) has also been transmitted to other 170S species, includ-
ing greater kudu, nyala, eland, scimitar-horned oryx, bison, rhesus 
macaque, domestic cat, and mink (13, 16, 81, 82). Conversely, pri-
ons generated in 170S animals are poorly transmissible to 170N 
recipients and vice versa. Transgenic mice overexpressing bovine or 
ovine PrP completely resisted infection to 9 different CWD isolates 
(58), and WT mice do not develop clinical prion disease after infec-
tion with elk CWD or hamster 263K scrapie (57, 58, 60). Further-
more, cattle and sheep are poorly infectible with mule deer CWD, 
since few animals develop disease after prolonged ips of 6 years, and 
only after intracerebral inoculation (83, 84). Among 170N animals, 
prions are also transmissible, as elk CWD is infectious to hamsters 
(85), albeit not very efficiently. Collectively, most historical data 
from studies on species barriers support the model that similar-
ity at the loop region, and particularly the 170S/N switch, impacts 
transmission barriers in a broad variety of species. As a possible 
exception to these observations, cattle may be susceptible to CWD 
from white-tailed deer (86). The latter finding suggests that specific 
prion strains can overrule the codon 170 homology requirement.
Does the β2-α2 loop direct prion strain conformation? What are the 
structural consequences of the substitutions at residues 170 and 
174, and how might they explain the important role of these sub-
stitutions in interspecies prion transmission? Crystallographic 
investigations of PrP peptides revealed that adjacent β2-α2 loops 
can engage in a “dry steric zipper” interface, which was proposed 
to represent the elemental backbone of many amyloids. Peptide 
crystal structures encompassing the β2-α2 loops bearing the 
170S/174N and 170N/174T substitutions were arranged in a 
Table 2
Serial automated PMCA using tg1020 brain homogenate as the substrate
Passage	 P3		 	 P4		 P5		
	 (no.	PrPSc-positive	tubes/total)	 (no.	PrPSc-positive	tubes/total)	 (no.	PrPSc-positive	tubes/total)
	 tga20	 tg1020	 tga20	 tg1020	 tga20	 tg1020
Unseeded	 0/6 0/6 0/6 0/6 0/6 0/6
RML	 6/6 6/6 6/6 6/6 6/6 6/6
Hamster scrapie	 0/6 1/6 0/6 5/6 1/6 6/6
Deer CWD	 1/6 2/6 3/6 3/6 3/6 5/6
Sheep scrapie	 0/6 0/6 0/6 0/6 0/6 0/6
Brains from tg1020 and tga20 mice were extracted after perfusion with PBS plus 5 mM EDTA and used as substrate or source of PrPC. Sixty μl of brain 
homogenates were treated in replicates of 6 (n = 6) with serial automated PMCA (91, 92) and were incubated/sonicated for 48 hours in each round. After 
each round of PMCA, the PK-resistant PrP (PrPSc) in the sonicated/incubated samples was analyzed by Western blotting and diluted 1:10 into a freshly 
prepared tg1020 or tga20 mouse brain homogenate to start the next PMCA round (from P1 to P5). This process was repeated for 5 rounds (P5). The frac-
tion of PrPSc-positive tubes is indicated for rounds P3 to P5 of PMCA.
Table 3
Interspecies transmission of TSEs in tga20 and tg1020 mice, as 
determined by PK-resistant PrPSc in brain
TSE	origin	 Transmission	to		 Transmission	to		
	 tga20	mice	 tg1020	mice
Mouse + +
Deer +A +
Hamster +/−B	 +
Cattle + −
Sheep + −
AWT mice are resistant (57). BOne out of four mice developed PrP 
aggregates in brain. Infection with prions is indicated by “+” and no 
infection is indicated by “–”.
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P1 or a P21 crystal space group, respectively (87). These observa-
tions suggest striking differences in the β-sheet alignment of PrPSc 
aggregates between prion-infected 170S and 170N animals and 
may provide a plausible starting point for clarifying the structural 
basis of prion species barriers that are highly relevant to public 
health, including the potential transmissibility of bovine and cer-
vid prions to humans.
Methods
Prion inoculations. tga20 or tg1020 (RL) transgenic mice, which overexpressed 
murine PrP (52, 53), were intracerebrally inoculated in the left parietal 
cortex with 30 μl of brain homogenate. This was either a 5%–10% brain 
homogenate from a terminally sick, naturally CWD-infected mule deer 
(provided by M. Miller, Colorado Division of Wildlife, Fort Collins, Col-
orado, USA), an uninfected control deer (reported in ref. 59), a 5% brain 
homogenate from a terminal, naturally scrapie-infected Suffolk sheep (n = 4 
mice) (provided by T. Spraker, Colorado State University, Fort Collins, Colo-
rado, USA), or a 5% brain homogenate from a naturally BSE-infected cow 
(n = 4 mice) (provided by A. Zurbriggen, University of Bern, Bern, Switzer-
land). Mice were monitored every second day, and TSE was diagnosed accord-
ing to clinical criteria, including ataxia, kyphosis, and hind leg paresis. Mice 
were sacrificed at the onset of terminal disease. Mice were maintained under 
specific pathogen–free conditions. All of the present studies were reviewed 
and approved by the animal care and use committee (Kantonales Veter-
inäramt Zürich) in the Zurich Cantonal Veterinary Office, Switzerland.
Western blots. The 10% brain or spleen homogenates were prepared in PBS, 
using a Precellys 24 Tissue Homogenizer. Extracts of 50–90 μg protein were 
diluted with a Tris-based buffer (10 mM Tris, 10 mM EDTA, 100 mM NaCl, 
0.5% NP40, and 0.5% DOC) and digested with 100 μg/ml PK for 30 minutes 
at 37°C. A SDS-based buffer was then added, and the samples were heated 
to 95°C for 5 minutes, prior to electrophoresis through a 12% Bis-Tris pre-
cast gel (Invitrogen), followed by transfer to a nitrocellulose membrane by 
wet blotting. Proteins were detected with anti-PrP POM1 antibody (epitope 
in the globular domain, amino acids 121–231) (88). For secondary detection, 
we used an HRP-conjugated anti-mouse IgG antibody (Zymed, Invitrogen). 
Signals were visualized with the ECL detection kit (Pierce). Sodium phos-
photungstic acid (NaPTA) precipitation was used when noted to enrich for 
PrPSc, prior to Western blotting, using published methods (89).
Histoblots. Histoblots were performed as reported in Taraboulos et al. 
(90), using up to 100 μg/ml of PK for the digestion of PrPC. Histoblots 
were developed using the anti-PrP POM1 antibody (88).
PTAA staining of frozen tissue sections. Frozen sections from mouse brain were 
dried for 1 hour and fixed in 100% and 70% ethanol for 10 minutes each. After 
washing with deionized water, sections were equilibrated in 100 mM sodium 
carbonate at pH 10.2 for 30 minutes. The PTAA was diluted in the sodium 
carbonate buffer (1 μg per 100 μl buffer) and added to the sections. The sec-
tions were incubated with PTAA for 30 minutes at room temperature and 
washed with sodium carbonate buffer. The spectra in the tissue were recorded 
with a Zeiss Axioplan 2 microscope, fitted with a Spectraview 4.0 (Applied 
Spectral Imaging) and a Spectra-Cube (interferometrical optical head SD 
300) module with cooled CCD camera, through a 470 nm/40 nm (LP 515) 
bandpass filter (Zeiss) in steps of 10 nm. The data were processed with Spec-
traView 3.0 EXPO. Spectra were collected from 10 individual spots within 3–4 
plaques, from a minimum of 3 different mice of each prion strain.
PTAA staining of formalin-fixed tissue sections. Paraffin-embedded, forma-
lin-fixed, and formic-acid treated brain sections were deparaffinized and 
treated with PK (10 μg/ml in PBS) for 10 minutes prior to staining. PTAA 
staining was performed as described above.
Histopathology and immunohistochemical stains. Two-μm-thick sections were 
cut onto positively charged silanized glass slides and stained with H&E or 
immunostained using antibodies for PrP (SAF84), for astrocytes (GFAP), 
or microglia (Iba1). For PrP staining, sections were deparaffinized, incu-
bated for 6 minutes in 98% formic acid, and then washed in distilled water 
for 5 minutes. Sections were heated to 100°C in a pressure cooker in citrate 
buffer (pH 6.0), cooled for 3 minutes, and washed in distilled water for 
5 minutes. Immunohistochemical stains were performed on an automated 
Nexus staining apparatus (Ventana Medical Systems), using an iVIEW DAB 
Detection Kit (Ventana Medical Systems). After incubation with protease 1 
(Ventana Medical Systems) for 16 minutes, sections were incubated with 
anti-PrP SAF-84 (SPI-bio; 1:200) for 32 minutes. Sections were counter-
stained with hematoxylin. GFAP immunohistochemistry (1:1,000 for 
24 minutes; DAKO) for astrocytes and Iba1 immunohistochemistry (1:2,500 
for 32 minutes; Wako Chemicals) for microglia were similarly performed, 
but with antigen retrieval, by heating to 100°C in EDTA buffer (pH 8.0).
Serial automated PMCA procedure. The whole process of in vitro prion rep-
lication, including the PrPSc detection of amplified samples, was performed 
following the basic conditions described previously (91–93). The optimiza-
tion of the technique was performed empirically, taking into account all 
modifiable parameters. Our optimal results were obtained using the fol-
lowing settings: 60 μl of sample, 70% of power of sonication, 30 minutes of 
incubation time, 20 seconds of constant sonication, 180 ml of water over 
the horn plate sonicator, and 37°C–38°C in the water of sonication.
Statistics. Continuous data are presented as mean ± SD. The ips, from 
inoculation to terminal prion disease, in the tga20 and tg1020 mice were 
compared using Student’s unpaired t test. Two-tailed P values of less than 
0.05 were considered significant. Statistical analyses were performed using 
GraphPad Prism.
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